ArticleJournal of hepatocellular carcinoma2023

Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis.

Jingzhong Ouyang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.